ACCEPTANCE OF INDIRECT COMPARISONS IN THE GERMAN EARLY BENEFIT ASSESSMENT

被引：0
|
作者：
Berkemeier, F. [1 ]
Bless, H. [1 ]
Reindl, S. [2 ]
Ballhausen, A. [3 ]
Maltz, A. [2 ]
机构：
[1] IGES Inst GmbH, Berlin, Germany
[2] IGES Inst GmbH, Nurnberg, Germany
[3] IGES Inst GmbH, Hamburg, Germany
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.1597
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PHP64
引用
收藏
页码：A663 / A663
页数：1
相关论文
共 50 条
  • [31] REVIEWING THE USE OF MATCHING ADJUSTED INDIRECT COMPARISONS IN HEALTH TECHNOLOGY ASSESSMENT SUBMISSIONS
    Hwang, S.
    Groff, M.
    Daniele, P.
    Tremblay, G.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S204 - S204
  • [32] Matching-Adjusted Indirect Comparisons in the assessment of hemato-oncological drugs
    Manuel Martinez-Sesmerol, Jose
    De Castro-Carpeno, Javier
    Lopez-de las Heras, Araceli
    Fernandez-Nistal, Alonso
    Javier Parrondo-Garcia, Francisco
    [J]. FARMACIA HOSPITALARIA, 2021, 45 (02) : 55 - 60
  • [33] THE IMPACT OF RESPONSE ASSESSMENT TIMING ON INDIRECT TREATMENT COMPARISONS (ITCS) - A SIMULATION STUDY
    Kanters, S.
    Wennersbusch, D.
    Harrigan, S.
    Zannat, N. E.
    Stilla, A. M.
    Yang, L.
    Zoratti, M. J.
    Limbrick-Oldfield, E. H.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S395 - S396
  • [34] Ten years of German benefit assessment: price analysis for drugs with unproven additional benefit
    Kleining, Katrin
    Laufenberg, Jan
    Thrun, Philip
    Ehlert, Dorothee
    Wasem, Juergen
    Bartol, Arne
    [J]. HEALTH ECONOMICS POLICY AND LAW, 2024, 19 (02) : 216 - 233
  • [35] GUIDELINES IN GERMAN EARLY BENEFIT ASSESSMENT - WHICH GUIDELINES ARE CONSIDERED BY FEDERAL JOINT COMMITTEE FOR DETERMINING THE APPROPRIATE COMPARATOR?
    Scheler, E.
    Stratil, A.
    Roxlau, T.
    Bonduelle, D.
    [J]. VALUE IN HEALTH, 2018, 21 : S197 - S197
  • [36] EVALUATING THE NEED FOR AUTOMATED TECHNOLOGY SOLUTIONS IN ANNUAL THERAPY COST CALCULATIONS IN GERMAN EARLY BENEFIT ASSESSMENT DOSSIERS
    Gossmann, J. A.
    Drews, J.
    Schnauffer, D.
    Rauch, M.
    Kullnigg, A.
    Meier, C.
    Otto, J.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S73 - S73
  • [37] ORPHAN DRUGS IN THE GERMAN EARLY BENEFIT ASSESSMENT- REAL WORLD VERSUS G-BA BUREAUCRACY
    Lebioda, A.
    Huelsebeck, M.
    Plantoer, S.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A485 - A485
  • [38] Treatment response in hemato-oncology in the context of the German early benefit assessment of drugs compared to clinical practice
    Baltes, Nannette
    Icks, Andrea
    Dintsios, Charalabos-Markos
    [J]. JOURNAL OF EVIDENCE BASED MEDICINE, 2023, 16 (04) : 451 - 454
  • [39] IN VITRO DATA AS COMPLEMENTARY EVIDENCE SOURCE FOR THE ASSESSMENT OF ANTIBIOTICS IN THE GERMAN BENEFIT ASSESSMENT?
    Mechelke, M.
    Worf, K.
    Eheberg, D.
    Roxlau, T.
    Bonduelle, D.
    [J]. VALUE IN HEALTH, 2019, 22 : S609 - S609
  • [40] Indirect Treatment Comparisons and Biologics
    Mauger, David
    Apter, Andrea J.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2019, 7 (01): : 131 - 133
12345